Tacalyx GmbH is a Germany-based biotechnology startup founded in 2019. The company is dedicated to developing innovative anti-cancer therapeutics to address the limited treatment options for metastatic malignant tumors. Tacalyx focuses on targeting cancer-specific carbohydrate antigens, known as Tumor Associated Carbohydrate Antigens (TACAs), found on the surfaces of cancer cells. These abnormal glycans are highly specific to cancer and play a significant role in tumor progression and virulence. With a recent €7.00M Seed Round investment from Thuja Capital in 11 June 2024, Tacalyx is poised to advance its promising research and development efforts in high-need cancer indications. Their compelling approach to addressing crucial unmet medical needs positions the company as an exciting prospect in the biotechnology, health care, health and wellness, and life sciences industries.
Tacalyx GmbH
Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need
Berlin, Germany
16 employees
Seed
Total: $14.00M
Biotechnology, Health Care +2
General Information
Get notified when Tacalyx GmbH moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Tacalyx GmbH
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Germany Market
Biotechnology
About Tacalyx GmbH
Taxonomy: Cancer therapeutics, Tumor-associated carbohydrate antigens, Metastatic tumors, Glycocalyx, Cancer-specific antigens, TACAs, Max-Planck-Institute of Colloids and Interfaces, Aberrant glycosylation, Carbohydrate synthesis, Antibody development, Immunotherapy, Cancer research, Medical innovation
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Seed Round | •••••• | 1 |
|
11 Jun 2024 |
| Seed Round | •••••• | 6 |
|
25 Sep 2019 |
Tacalyx GmbH Alternatives & Competitors
A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers.
Pioneering immune-based therapies to harness the body's defenses against cancer through advanced imm...
LIQUID BIOPSY using disposable microfluidics to detect, take image, sort of Circulating Tumor Cells...
FAQ About Tacalyx GmbH
Don't just browse. Track.
Signal Tracker monitors Tacalyx GmbH and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.